December 14, 2024 08:45 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Pushpa 2 stampede: Allu Arjun walks out of jail, actor's lawyer slams delay in release | Donald Trump intends to end 'inconvenient' and 'very costly' Daylight Saving Time | Suchir Balaji: Indian-origin former OpenAI researcher found dead at US apartment | Bengaluru techie suicide: Karnataka Police issues summons to wife Nikita, her family members | French President Macron appoints centrist leader Francois Bayrou as new Prime Minister | Congress always prioritised personal interest over Constitution: Rajnath Singh | Jaishankar calls attack on Hindus in Bangladesh 'a source of concern' | Allu Arjun arrested over woman's death in stampede during Pushpa 2 premiere show | RBI receives bomb threat in Russian language, case filed | UP teenager kills mother, lives with body for 5 days
Conjugate drug extends survival in patients with advanced HER2-positive breast cancer, trial shows

Conjugate drug extends survival in patients with advanced HER2-positive breast cancer, trial shows

May 19, 2017, at 11:18 pm

New York, May 19 (IBNS): Women with HER2-positive breast cancer that worsened after previous treatment, survived significantly longer, on average, with a combination antibody/chemotherapy drug than with other treatments, an international phase 3 clinical trial led by researchers at Dana-Farber Cancer Institute and in Belgium has found.